Biomea Fusion, Inc. (BMEA)
1.42
+0.05
(+3.65%)
USD |
NASDAQ |
Oct 09, 16:00
1.415
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Free Cash Flow : -47.06M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -47.06M |
| March 31, 2026 | -56.37M |
| December 31, 2025 | -70.37M |
| September 30, 2025 | -87.27M |
| June 30, 2025 | -100.49M |
| March 31, 2025 | -113.86M |
| December 31, 2024 | -120.26M |
| September 30, 2024 | -113.02M |
| June 30, 2024 | -111.55M |
| March 31, 2024 | -105.08M |
| December 31, 2023 | -99.96M |
| September 30, 2023 | -98.03M |
| Date | Value |
|---|---|
| June 30, 2023 | -90.84M |
| March 31, 2023 | -80.31M |
| December 31, 2022 | -63.45M |
| September 30, 2022 | -58.73M |
| June 30, 2022 | -53.01M |
| March 31, 2022 | -44.56M |
| December 31, 2021 | -38.61M |
| September 30, 2021 | -25.19M |
| June 30, 2021 | -15.28M |
| March 31, 2021 | -8.40M |
| December 31, 2020 | -4.51M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| REGENXBIO, Inc. | -249.67M |
| Compass Therapeutics, Inc. | -56.38M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -10.03M |
| Cash from Financing (Quarterly) | 0.159M |
| Free Cash Flow Per Share (Quarterly) | -0.1386 |
| Free Cash Flow to Equity (Quarterly) | -9.666M |
| Free Cash Flow to Firm (Quarterly) | -10.03M |
| Free Cash Flow Yield | -47.89% |